ATE277933T1 - THIOPHENE COMPOUNDS FOR USE AS ANTICANCER AGENTS - Google Patents

THIOPHENE COMPOUNDS FOR USE AS ANTICANCER AGENTS

Info

Publication number
ATE277933T1
ATE277933T1 AT01925786T AT01925786T ATE277933T1 AT E277933 T1 ATE277933 T1 AT E277933T1 AT 01925786 T AT01925786 T AT 01925786T AT 01925786 T AT01925786 T AT 01925786T AT E277933 T1 ATE277933 T1 AT E277933T1
Authority
AT
Austria
Prior art keywords
anticancer agents
thiophene compounds
thiophene
compounds
anticancer
Prior art date
Application number
AT01925786T
Other languages
German (de)
Inventor
Michael Joseph Luzzio
Matthew Arnold Marx
Bingwei Vera Yang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE277933T1 publication Critical patent/ATE277933T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT01925786T 2000-06-06 2001-05-02 THIOPHENE COMPOUNDS FOR USE AS ANTICANCER AGENTS ATE277933T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20968600P 2000-06-06 2000-06-06
PCT/IB2001/000766 WO2001094353A1 (en) 2000-06-06 2001-05-02 Thiophene derivatives useful as anticancer agents

Publications (1)

Publication Number Publication Date
ATE277933T1 true ATE277933T1 (en) 2004-10-15

Family

ID=22779830

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01925786T ATE277933T1 (en) 2000-06-06 2001-05-02 THIOPHENE COMPOUNDS FOR USE AS ANTICANCER AGENTS

Country Status (22)

Country Link
US (1) US6964961B2 (en)
EP (1) EP1287001B1 (en)
JP (1) JP2003535867A (en)
AR (1) AR032621A1 (en)
AT (1) ATE277933T1 (en)
AU (1) AU2001252463A1 (en)
BR (1) BR0111377A (en)
CA (1) CA2411084A1 (en)
DE (1) DE60106022T2 (en)
DO (1) DOP2001000170A (en)
EC (1) ECSP014097A (en)
ES (1) ES2223827T3 (en)
GT (1) GT200100104A (en)
MX (1) MXPA02012034A (en)
PA (1) PA8518701A1 (en)
PE (1) PE20011373A1 (en)
PT (1) PT1287001E (en)
SV (1) SV2002000478A (en)
TN (1) TNSN01082A1 (en)
TR (1) TR200402656T4 (en)
UY (1) UY26750A1 (en)
WO (1) WO2001094353A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2377771A1 (en) * 1999-07-01 2001-01-11 Ajinomoto Co., Inc. Heterocyclic compounds and medical use thereof
IL154034A0 (en) * 2000-08-09 2003-07-31 Astrazeneca Ab Indole, azaindole and indazole derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals
DE10164139A1 (en) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
US7101898B2 (en) 2002-02-01 2006-09-05 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
CA2473468C (en) * 2002-02-01 2011-06-21 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
MXPA04008403A (en) 2002-03-01 2004-11-26 Pfizer iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS.
WO2003103661A1 (en) * 2002-06-06 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
CL2003002287A1 (en) * 2002-11-25 2005-01-14 Wyeth Corp COMPOUNDS DERIVED FROM TIENO [3,2-b] -PIRIDINA-6-CARBONITRILOS AND TIENEO [2,3-b] -PIRIDINA-5-CARBONITRILS, PHARMACEUTICAL COMPOSITION, PROCEDURE OF PREPARATION AND INTERMEDIARY COMPOUNDS, AND THEIR USE IN THE TREATMENT OF CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
AU2004215644B2 (en) 2003-02-27 2010-09-02 Palau Pharma, S.A. Pyrazolopyridine derivates
US7592352B2 (en) * 2003-05-06 2009-09-22 Smithkline Beecham Corporation Substituted thieno and furo-pyridines
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
DK1660090T3 (en) 2003-08-14 2012-12-17 Array Biopharma Inc QUINAZOLINE ANALOGS AS RECEPTOR-TYROSINKINASE INHIBITORS
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
KR101257343B1 (en) 2004-07-30 2013-04-23 메틸진 인코포레이티드 Inhibitors of vegf receptor and hgf receptor signaling
BRPI0610322B8 (en) 2005-05-20 2021-05-25 Methylgene Inc vegf receptor and hgf receptor signaling inhibitors and pharmaceutical composition
ES2473341T3 (en) 2005-05-20 2014-07-04 Methylgene Inc Inhibitors of VEGF receptor and HGF receptor signaling
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
AR056200A1 (en) * 2005-09-27 2007-09-26 Wyeth Corp TIENO [2,3-B] PIRIDIN-5-CARBONITRILS AS INHIBITORS OF PROTEIN KINASE
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
EP1971601B1 (en) 2005-11-15 2009-10-21 Array Biopharma Inc. N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
CA2636242A1 (en) * 2006-01-30 2008-05-29 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
WO2008124083A2 (en) 2007-04-05 2008-10-16 Amgen Inc. Aurora kinase modulators and method of use
BRPI0923670A2 (en) 2008-03-05 2013-07-30 Methylgene Inc protein tyrosine kinase activity inhibitors and their use, as well as a composition comprising them
WO2009117157A1 (en) 2008-03-20 2009-09-24 Amgen Inc. Aurora kinase modulators and method of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
CA3017886A1 (en) 2008-11-19 2010-05-27 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MX2011011972A (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals Inc Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors.
DK3029039T3 (en) 2010-05-17 2017-12-04 Forum Pharmaceuticals Inc PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
FR3080620B1 (en) * 2018-04-27 2021-11-12 Univ Paris Sud COMPOUNDS WITH TUBULIN POLYMERIZATION INHIBITOR ACTIVITY AND IMMUNOMODULATORY PROPERTIES
CN113648307B (en) * 2021-09-23 2022-09-30 河南大学 MII-tt-DTT and application thereof in preparing anti-colorectal cancer drugs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3277623D1 (en) 1981-07-31 1987-12-17 Sloan Kettering Inst Cancer Anti-leukemic beta-glycosyl c-nucleosides
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
JPH02256667A (en) * 1988-12-27 1990-10-17 Masatoshi Yamato Condensed quinoline-based compound and production thereof
CA2039411A1 (en) 1990-03-30 1991-10-01 Ronnie Gerald Edie Thienopyrimidine derivatives
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
WO1993017021A1 (en) 1992-02-19 1993-09-02 Pfizer, Inc. Heterocyclic compounds for enhancing antitumor activity
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
CA2223081C (en) 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
AR004010A1 (en) 1995-10-11 1998-09-30 Glaxo Group Ltd HETERO CYCLIC COMPOUNDS
ATE243697T1 (en) 1995-12-08 2003-07-15 Pfizer SUBSTITUTED HETEROCYCLIC DERIVATIVES AS CRF ANTAGONISTS
PT882051E (en) 1996-02-07 2002-04-29 Janssen Pharmaceutica Nv THYOPHENOPYRIMIDINES
IL129825A0 (en) 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
EP1028964A1 (en) * 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents

Also Published As

Publication number Publication date
AR032621A1 (en) 2003-11-19
EP1287001A1 (en) 2003-03-05
MXPA02012034A (en) 2003-04-25
WO2001094353A1 (en) 2001-12-13
DOP2001000170A (en) 2002-05-15
PE20011373A1 (en) 2002-01-18
US20020042409A1 (en) 2002-04-11
PA8518701A1 (en) 2002-09-17
UY26750A1 (en) 2002-01-31
CA2411084A1 (en) 2001-12-13
DE60106022D1 (en) 2004-11-04
TR200402656T4 (en) 2004-11-22
DE60106022T2 (en) 2006-03-09
TNSN01082A1 (en) 2005-11-10
ECSP014097A (en) 2003-02-06
JP2003535867A (en) 2003-12-02
GT200100104A (en) 2002-01-31
EP1287001B1 (en) 2004-09-29
BR0111377A (en) 2003-06-03
PT1287001E (en) 2004-12-31
ES2223827T3 (en) 2005-03-01
AU2001252463A1 (en) 2001-12-17
SV2002000478A (en) 2002-07-03
US6964961B2 (en) 2005-11-15

Similar Documents

Publication Publication Date Title
ATE277933T1 (en) THIOPHENE COMPOUNDS FOR USE AS ANTICANCER AGENTS
DE60115937D1 (en) Piperidin compounds for use as antiallergic agents
ATE485272T1 (en) POLYARYLCARBOXAMIDE FOR USE AS A LIPIDE LOWERING AGENT
NO20032585L (en) ABCA-1 raising compounds
NO20026253L (en) Organic compounds
DE60134094D1 (en) C7-TAXANESTER AS ANTITUMORANT
NO20026196L (en) Kinazolinditosylatsalt compounds
DK1619192T3 (en) Aryl-condensed azapolycyclic compounds
IS6267A (en) New spiro compounds
IS6024A (en) New compounds
EE200200033A (en) New compounds
IS6139A (en) New compounds
ATE428420T1 (en) SUBSTITUTED 8-ARYLCINOLINES AS PHOSPHODIESTERASE-4 INHIBITORS
DE50011908D1 (en) 16-HYDROXYESTRATRIENE AS SELECTIVELY EFFECTIVE ESTROGENE
DE50107230D1 (en) SULPHAMIDOTHIENOPYRIMIDINE FOR USE AS PHOSPHODIESTERASE V-HEMMER
IS6657A (en) New compounds
DE50206096D1 (en) SUBSTITUTED BENZOÄBÜAZEPIN-2-ON COMPOUNDS AS PAIN
ATE372338T1 (en) DESHALOGEN COMPOUNDS
NO20031837D0 (en) Calcilitic compounds
NO20030303L (en) Calcilitic compounds
NO20023508D0 (en) Calcilitic compounds
ATE280161T1 (en) IMIDAZOLE COMPOUNDS AS ALPHA2-ADRENORECEPTOR ANTAGONISTS
AR028399A1 (en) NEW COMPOUNDS
DE29904387U1 (en) Scented sand
SE0003437D0 (en) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1287001

Country of ref document: EP

REN Ceased due to non-payment of the annual fee